Eli Lilly Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Dave Ricks

İcra Kurulu Başkanı

US$29.2m

Toplam tazminat

CEO maaş yüzdesi	5.78%
CEO görev süresi	9yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	5.9yrs
Yönetim Kurulu ortalama görev süresi	9.6yrs

Son yönetim güncellemeleri

Recent updates

Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)

Dec 24

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Nov 25

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 07

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Sep 19Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.

Eli Lilly and Company Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

May 05

CEO Tazminat Analizi

Dave Ricks'un ücretlendirmesi Eli Lilly'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2025	n/a	n/a	US$18b
Jun 30 2025	n/a	n/a	US$14b
Mar 31 2025	n/a	n/a	US$11b
Dec 31 2024	US$29m	US$2m	US$11b
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b

Tazminat ve Piyasa: Dave 'nin toplam tazminatı ($USD 29.24M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 13.47M ).

Tazminat ve Kazançlar: Dave 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dave Ricks (57 yo)

9yrs

Görev süresi

US$29,242,926

Tazminat

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Ricks	Chairman	9yrs	US$29.24m	0.082% $ 789.0m
Lucas Montarce	Executive VP & CFO	1.3yrs	US$2.95m	0.0016% $ 15.8m
Daniel Skovronsky	Chief Scientific & Product Officer and President of Lilly Research Laboratories	7.6yrs	US$12.64m	0.024% $ 229.0m
Anat Hakim	Executive VP	5.9yrs	US$7.48m	0.0049% $ 46.8m
Jacob Van Naarden	Executive VP & President of Lilly Oncology	no data	US$5.77m	0.0033% $ 31.4m
Gordon Brooks	Group VP	1.5yrs	US$2.74m	0.0022% $ 21.4m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	13.2yrs	Veri yok	0.00051% $ 4.9m
Diogo Rau	EVP & Chief Information and Digital Officer	4.7yrs	US$5.10m	0.0022% $ 21.2m
Eric Dozier	Executive VP & Chief People Officer	3.1yrs	Veri yok	0.0011% $ 11.0m
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	18yrs	US$5.38m	Veri yok
W. Moody	SVP of Global Active Pharmaceutical Ingredient	9.4yrs	Veri yok	Veri yok
Ilya Yuffa	Executive VP and President of Lilly USA & Global Customer Capabilities	5.3yrs	Veri yok	0.0029% $ 28.2m

5.9yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: LLY 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Ricks	Chairman	9yrs	US$29.24m	0.082% $ 789.0m
Gaby Sulzberger	Independent Director	5yrs	US$366.75k	Veri yok
Sidney Taurel	Chairman Emeritus	17yrs	US$13.06m	Veri yok
Jon Erik Fyrwald	Independent Director	20.2yrs	US$386.55k	0.00019% $ 1.8m
Ralph Alvarez	Independent Director	16.8yrs	US$361.00k	0.000080% $ 769.8k
Carolyn Bertozzi	Independent Director	less than a year	US$196.00k	0.00022% $ 2.1m
William Kaelin	Independent Director	13.6yrs	US$400.15k	Veri yok
Mary Hedley	Independent Director	3.7yrs	US$339.00k	0.000040% $ 384.9k
Juan Luciano	Lead Independent Director	9.9yrs	US$398.00k	Veri yok
Katherine Baicker	Independent Director	14.1yrs	US$361.00k	Veri yok
Jamere Jackson	Independent Director	9.3yrs	US$365.00k	0.000020% $ 192.4k
Kimberly Johnson	Independent Director	4.9yrs	US$336.00k	Veri yok

9.6yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LLY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/01/02 13:58
Gün Sonu Hisse Fiyatı	2026/01/02 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Eli Lilly and Company 53 Bu analistlerden 29, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Kerry Holford	Berenberg
Luisa Hector	Berenberg

Eli Lilly Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Chairman recently bought US$1.1m worth of stock

Recent updates

Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).

Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Dividend of US$1.73 announced

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Insufficient new directors

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Now 20% undervalued

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Price target increased by 7.4% to US$1,007

Price target increased by 7.8% to US$993

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Second quarter dividend of US$1.50 announced

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative Colitis

Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative Colitis

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche Trial

Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 Trials

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four Years

Investor sentiment improves as stock rises 16%

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast Cancer

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of Mounjaro

Eli Lilly and Company Announces Positive Topline Results from ACHIEVE-3

Eli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research Investment

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of Jaypirca

Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung Cancer

Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE Trial

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-2 Trial

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Chairman recently bought US$1.1m worth of stock

Ken Paxton Files Lawsuit in State Court Against Eli Lilly and Co

Chairman recently bought US$1.1m worth of stock

Chairman recently bought US$1.1m worth of stock

New major risk - Earnings quality

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of US$1.50 per share

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Eli Lilly and Company Announces Topline Results from SURPASS-CVOT

Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 Study

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of Jaypirca

Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's Disease

Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025

Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease

First quarter dividend of US$1.50 announced

Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025

Eli Lilly and Company Announces Detailed Results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Investigational Once-Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone

Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

Lilly to Offer All Approve Doses of Zepbound (Tirzepatide) Single-Dose Vials Through LillyDirect Self Pay Pharmacy Solutions

Eli Lilly Reportedly Nears $1.3 Billion Deal for Verve Therapeutics

Eli Lilly and Company Presents First Clinical Data for Its Investigational, Next-Generation Fra Targeting Adc in Platinum-Resistant Ovarian Cancer At the 2025 Asco Annual Meeting

Eli Lilly and Company (NYSE:LLY) agreed to acquire SiteOne Therapeutics, Inc. for $1 billion.

Eli Lilly and Company Announces Details of Presentation at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Eli Lilly and Company Receives Marketing Authorization in Australia for the Treatment of Early Symptomatic Alzheimer's Disease

Eli Lilly and Company Announces Zepbound (Tirzepatide) Showed Superior Weight Loss over Wegovy (Semaglutide) in Complete Surmount-5 Results Published in the New England Journal of Medicine

First quarter dividend of US$1.50 announced